Ozette’s proprietary technology eliminates manual gridlock and provides unmatched speed, resolution, and reproducibility to unlock immunotherapy breakthroughs from pre-clinical to post-market.
Ozette Technologies, Inc., a technology-driven life sciences startup engineering a transformative leap in cell discovery and annotation of the human immune system, today announced its $26MM Series A funding, led by Madrona Ventures. Other participating investors include Cercano Management (formerly Vulcan Capital), M12, Microsoft’s venture fund, Alexandria Venture Investments, OCV Partners and Duke University.
“This funding is a testament to the Ozette team and mission, the unique position they hold in the market, and the immense confidence from the industry as they rapidly scale their work helping industry treat and prevent disease.” Tweet this
Ozette’s intelligent computational analysis technology unlocks the full potential of single-cell data. The AI-powered analysis, rooted in research pioneered at the Fred Hutchinson Cancer Center and incubated at the Allen Institute for Artificial Intelligence (AI2), reveals high-resolution, reliable insights an order of magnitude faster than the gold standard manual analysis. Ozette’s early partners include small to large biopharma developing therapies in oncology, autoimmune disorders and infectious disease. The speed and resolution of Ozette’s automated insight generation unlocks new frontiers in computational immunology, accelerating the next wave in biomarker and drug discovery.
The new funding will fuel company growth and enable Ozette to expand its capabilities across a multiomic platform, integrating single cell proteomics and transcriptomics. A new state-of-the-art immunology lab in development will soon offer another asset and avenue for partners to leverage Ozette’s technology, further enabling vertically integrated, automated analysis for immune insights.
“Ozette’s technology alleviates partners from labor intensive, manual analysis methods and propels us towards a future with integrated, searchable immune data that transforms therapeutic discovery and development,” said Dr. Ali Ansary, CEO and Co-founder of Ozette.
“We’ve engineered a machine learning-based computational platform that completes months of analysis work in a matter of days, and we’re working on reducing that to minutes. Ozette represents the first line of innovation towards a fully resolved portrait of the immune state at the cellular level, providing transparent, verifiable, and reproducible high-resolution insights that scientists can trust.”
Despite its relatively young age, Ozette’s technology has been pivotal in a number of immunological discoveries which have reached publication. In a 2021 study, Ozette’s technology was able to automatically resolve several hundred distinct immune cell populations, and find a correlation between drug response and a set of rare cell populations that had never been characterized previously. Ozette has continued to work with the Cancer Immunotherapy Trials Network and other partners to look at over $100M of clinical trial data to date. Breakthrough scientific research that used Ozette’s core technology recently published in Nature identified a subset of T cells that appear to shield solid tumors from immune attack, helping explain why cutting-edge immunotherapies that work against blood cancers are less effective against solid tumors and forging a path for future drugs and therapies that address this nuance.
“Ozette’s prescient technology is realizing the future of better healthcare today with unprecedented vision, speed, and invaluable context to unlock how our immune system responds to adversity. We continue to back industry’s most brilliant scientific and technological minds that are driving innovation as they break traditional biotech barriers using intelligent applications to unite disciplines for the greater good,” said Matt McIlwain, Managing Director at Madrona. “This funding is a testament to the Ozette team and mission, the unique position they hold in the market, and the immense confidence from the industry as they rapidly scale their work helping industry treat and prevent disease.”
Ozette’s interdisciplinary team is made up of a deep bench of scientists, engineers and designers with a wide range of experience spanning Genentech, Google, Microsoft, Amazon, Airbnb, and more. Notable recent hires include Amarjit Kaur, VP of Engineering at Ozette, previously with SayKara/Nuance (acquired by Microsoft).
“Everything we do, from research and partnerships to company growth, is centered around valuing people first and is working toward our vision for a future when life-saving and life-improving drugs reach market faster,” said Ansary.
Ozette is growing its team, including engineering, product management, research and development, translational science, and business development.
See open positions here.
Follow Ozette on LinkedIn and Twitter for the latest news and information.
Ozette Technologies, Inc. is engineering a transformative leap in cell discovery and annotation of the human immune system. The Seattle-based (remote-first) life sciences technology startup is building a groundbreaking high-resolution, intelligent, single-cell immune monitoring platform and corpus of high-resolution data leveraging its novel AI technologies. Founded in late 2020, Ozette was spun-out from the Fred Hutchinson Cancer Center and incubated at the Allen Institute for AI. Ozette’s interdisciplinary team is made up of a deep bench of scientists, engineers, and designers with a wide range of experience spanning Genentech, Google, Microsoft, Amazon, Airbnb, and more. Ozette’s team also includes leaders and pioneers in the field of medical research and single cell analysis, including its founders: physician Ali Ansary, and scientists Greg Finak, Evan Greene, and Raphael Gottardo.